|
1
|
Pattanaik D, Brown M, Postlethwaite BC and
Postlethwaite AE: Pathogenesis of systemic sclerosis. Front
Immunol. 6:2722015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi MY and Fritzler MJ: Progress in
understanding the diagnostic and pathogenic role of autoantibodies
associated with systemic sclerosis. Curr Opin Rheumatol.
28:586–594. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crincoli V, Fatone L, Fanelli M, Rotolo
RP, Chialà A, Favia G and Lapadula G: Orofacial manifestations and
temporomandibular disorders of systemic scleroderma: An
observational study. Int J Mol Sci. 17:11892016. View Article : Google Scholar
|
|
4
|
Paik JJ, Wigley FM, Mejia AF and Hummers
LK: Independent association of severity of muscle weakness with
disability as measured by the health assessment questionnaire
disability index in scleroderma. Arthritis Care Res (Hoboken).
68:1695–1703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bretterklieber A, Painsi C, Avian A, Wutte
N and Aberer E: Impaired quality of life in patients with systemic
sclerosis compared to the general population and chronic
dermatoses. BMC Res Notes. 7:5942014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen C, Ranque B, Baubet T, Bérezné A,
Mestre-Stanislas C, Rannou F, Papelard A, Morell-Dubois S, Revel M,
Moro MR, et al Groupe Français de Recherche sur la Sclérodermie, :
Clinical, functional and health-related quality of life correlates
of clinically significant symptoms of anxiety and depression in
patients with systemic sclerosis: A cross-sectional survey. PLoS
One. 9:e904842014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sandqvist G, Hesselstrand R, Petersson IF
and Kristensen LE: Work disability in early systemic sclerosis: A
longitudinal population-based cohort study. J Rheumatol.
42:1794–1800. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jaeger VK, Distler O, Maurer B, Czirják L,
Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton
C, et al: Functional disability and its predictors in systemic
sclerosis: A study from the DeSScipher project within the EUSTAR
group. Rheumatology (Oxford). 57:441–450. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ziemek J, Man A, Hinchcliff M, Varga J,
Simms RW and Lafyatis R: The relationship between skin symptoms and
the scleroderma modification of the health assessment
questionnaire, the modified Rodnan skin score, and skin pathology
in patients with systemic sclerosis. Rheumatology (Oxford).
55:911–917. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morrisroe K, Stevens W, Huq M, Prior D,
Sahhar J, Ngian GS, Celermajer D, Zochling J, Proudman S and
Nikpour M; Australian Scleroderma Interest Group (ASIG), : Survival
and quality of life in incident systemic sclerosis-related
pulmonary arterial hypertension. Arthritis Res Ther. 19:1222017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Denton CP: Systemic sclerosis: From
pathogenesis to targeted therapy. Clin Exp Rheumatol. 33 (Suppl
92):S3–S7. 2015.PubMed/NCBI
|
|
12
|
Denton CP: Advances in pathogenesis and
treatment of systemic sclerosis. Clin Med (Lond). 16:55–60. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burlui A, Cardoneanu A, Macovei LA, Arhire
L, Graur M and Rezus E: Is there a place for anti-nucleosome
antibody assessment in scleroderma? Rom J Rheumatol. 27:169–173.
2018.
|
|
14
|
Ilie AC, Alexa ID, Moroșanu AI, Covic A
and Cepoi V: Effects of oxidative stress and pharmacologycal
treatment on geriatric syndromes in the hospitalised elderly
patients. Farmacia. 64:588–593. 2016.
|
|
15
|
Rezuș E, Cardoneanu A, Burlui A, Luca A,
Codreanu C, Tamba BI, Stanciu GD, Dima N, Bădescu C and Rezuș C:
The Link Between Inflammaging and Degenerative Joint Diseases. Int
J Mol Sci. 20:6142019. View Article : Google Scholar
|
|
16
|
Shiwen X, Leask A, Abraham DJ and Fonseca
C: Endothelin receptor selectivity: Evidence from in vitro and
pre-clinical models of scleroderma. Eur J Clin Invest. 39 (Suppl
2):19–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ortega Mateo A and de Artiñano AA:
Highlights on endothelins: A review. Pharmacol Res. 36:339–351.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi-Wen X, Rodríguez-Pascual F, Lamas S,
Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP,
Black CM, et al: Constitutive ALK5-independent c-Jun N-terminal
kinase activation contributes to endothelin-1 overexpression in
pulmonary fibrosis: Evidence of an autocrine endothelin loop
operating through the endothelin A and B receptors. Mol Cell Biol.
26:5518–5527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mouthon L, Mestre-Stanislas C, Bérezné A,
Rannou F, Guilpain P, Revel M, Pagnoux C, Guillevin L, Fermanian J
and Poiraudeau S: Impact of digital ulcers on disability and
health-related quality of life in systemic sclerosis. Ann Rheum
Dis. 69:214–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li W and Frech TM: The critical need for
accurately defining digital ulcers in scleroderma. J Scleroderma
Relat Disord. 2:69–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schieir O, Thombs BD, Hudson M, Boivin JF,
Steele R, Bernatsky S, Hanley J and Baron M; Canadian Scleroderma
Research Group, : Prevalence, severity, and clinical correlates of
pain in patients with systemic sclerosis. Arthritis Care Res
(Hoboken). 62:409–417. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mouthon L, Carpentier PH, Lok C, Clerson
P, Gressin V, Hachulla E, Bérezné A, Diot E, Van Kien AK, Jego P,
et al ECLIPSE study investigators, : Controlling the digital
ulcerative disease in systemic sclerosis is associated with
improved hand function. Semin Arthritis Rheum. 46:759–766. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bose N, Bena J and Chatterjee S:
Evaluation of the effect of ambrisentan on digital microvascular
flow in patients with systemic sclerosis using laser Doppler
perfusion imaging: A 12-week randomized double-blind placebo
controlled trial. Arthritis Res Ther. 17:442015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rezuş E, Floria M, Grigoriu A, Tamba BI
and Rezus C: Cardiovascular Risk Factors in Chronic Inflammatory
Rheumatic Diseases: Modern Assessment and Diagnosis. Curr Vasc
Pharmacol. 13:716–724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Avouac J, Walker U, Tyndall A, Kahan A,
Matucci-Cerinic M, Allanore Y, Miniati I, Muller A, Iannone F,
Distler O, et al EUSTAR, : Characteristics of joint involvement and
relationships with systemic inflammation in systemic sclerosis:
Results from the EULAR Scleroderma Trial and Research Group
(EUSTAR) database. J Rheumatol. 37:1488–1501. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Diab S, Dostrovsky N, Hudson M, Tatibouet
S, Fritzler MJ, Baron M and Khalidi N; Canadian Scleroderma
Research Group, : Systemic sclerosis sine scleroderma: A
multicenter study of 1417 subjects. J Rheumatol. 41:2179–2185.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oldfield V and Lyseng-Williamson KA:
Bosentan: A review of its use in pulmonary arterial hypertension
and systemic sclerosis. Am J Cardiovasc Drugs. 6:189–208. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nadashkevich O, Davis P, Fritzler M and
Kovalenko W: A randomized unblinded trial of cyclophosphamide
versus azathioprine in the treatment of systemic sclerosis. Clin
Rheumatol. 25:205–212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Badesch DB, Hill NS, Burgess G, Rubin LJ,
Barst RJ, Galiè N and Simonneau G; SUPER Study Group, : Sildenafil
for pulmonary arterial hypertension associated with connective
tissue disease. J Rheumatol. 34:2417–2422. 2007.PubMed/NCBI
|
|
30
|
Galiè N, Brundage BH, Ghofrani HA, Oudiz
RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth
A, et al Pulmonary Arterial Hypertension and Response to Tadalafil
(PHIRST) Study Group, : Tadalafil therapy for pulmonary arterial
hypertension. Circulation. 119:2894–2903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barst RJ, McGoon M, McLaughlin V, Tapson
V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, et
al Beraprost Study Group, : Beraprost therapy for pulmonary
arterial hypertension. J Am Coll Cardiol. 41:2119–2125. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Galiè N, Humbert M, Vachiéry JL, Vizza CD,
Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, et
al Arterial Pulmonary Hypertension and Beraprost European
(ALPHABET) Study Group, : Effects of beraprost sodium, an oral
prostacyclin analogue, in patients with pulmonary arterial
hypertension: A randomized, double-blind, placebo-controlled trial.
J Am Coll Cardiol. 39:1496–1502. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vacca A, Meune C, Gordon J, Chung L,
Proudman S, Assassi S, Nikpour M, Rodriguez-Reyna TS, Khanna D,
Lafyatis R, et al Scleroderma Clinical Trial Consortium Cardiac
Subcommittee, : Cardiac arrhythmias and conduction defects in
systemic sclerosis. Rheumatology (Oxford). 53:1172–1177. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gheorghevici TS, Veliceasa B, Puha B,
Toader S, Alexa ID and Alexa O: Preoperative Hemoglobin Dynamics in
Patients with Trochanteric Fractures. A multivariate analysis. Rev
Chim Buchar. 69:3320–3324. 2018.
|
|
35
|
Khanna D, Hays RD and Furst DE: Functional
disability and other health-related quality-of-life domains: Points
to consider for clinical trials in systemic sclerosis. Rheumatology
(Oxford). 56 (Suppl 5):v17–v22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baron M, Hudson M, Tatibouet S, Steele R,
Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, et al:
The Canadian systemic sclerosis oral health study: Orofacial
manifestations and oral health-related quality of life in systemic
sclerosis compared with the general population. Rheumatology
(Oxford). 53:1386–1394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burlui A, Graur M, Gherasim A, Cardoneanu
A and Rezuş E: The role of adipokines in inflammation and
connective tissue diseases: Can we face the challenge? Int J Med
Dent. 8:26–33. 2018.
|
|
38
|
Siegert E, March C, Otten L, Makowka A,
Preis E, Buttgereit F, Riemekasten G, Müller-Werdan U and Norman K:
Prevalence of sarcopenia in systemic sclerosis: Assessing body
composition and functional disability in patients with systemic
sclerosis. Nutrition. 55-56:51–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
De Cata A, Inglese M, Molinaro F, De Cosmo
S, Rubino R, Bernal M and Mazzoccoli G: Digital ulcers in
scleroderma patients: A retrospective observational study. Int J
Immunopathol Pharmacol. 29:180–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ughi N, Crotti C and Ingegnoli F:
Effectiveness and safety of oxycodone/naloxone in the management of
chronic pain in patients with systemic sclerosis with recurrent
digital ulcers: Two case reports. Clin Interv Aging. 11:307–311.
2016.PubMed/NCBI
|
|
41
|
Merz EL, Assassi S and Malcarne VL: Pain
and Its Management in Systemic Sclerosis. Curr Treatm Opt
Rheumatol. 4:255–267. 2018. View Article : Google Scholar
|
|
42
|
Alexa T, Marza A, Voloseniuc T and Tamba
B: Enhanced analgesic effects of tramadol and common trace element
coadministration in mice. J Neurosci Res. 93:1534–1541. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luca FA, Ioan CA, Sasu C and Luca AC: The
Impact of Public Health Care Services on the Patients' Perception
as Regards the Health Institutions Brand on the Background of the
Health Reform in Romania. Rev Res Soc Intervention. 49:802015.
|
|
44
|
Carausu EM, Paris S, Burlea LS, Tucmeanu
AI and Antohe I: The Crisis Impact on the Romanian Health System
and Population Health. Rev Res Soc Intervention. 57:120–137.
2017.
|
|
45
|
Peytrignet S, Denton CP, Lunt M,
Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L,
Distler JHW, et al: Disability, fatigue, pain and their associates
in early diffuse cutaneous systemic sclerosis: The European
Scleroderma Observational Study. Rheumatology (Oxford). 57:370–381.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Herrick AL, Pan X, Peytrignet S, Lunt M,
Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler
JHW, et al: Treatment outcome in early diffuse cutaneous systemic
sclerosis: The European Scleroderma Observational Study (ESOS). Ann
Rheum Dis. 76:1207–1218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lambova S: Cardiac manifestations in
systemic sclerosis. World J Cardiol. 6:993–1005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wallace B, Kafaja S, Furst DE, Berrocal
VJ, Merkel PA, Seibold JR, Mayes MD and Khanna D: Reliability,
validity and responsiveness to change of the Saint George's
Respiratory Questionnaire in early diffuse cutaneous systemic
sclerosis. Rheumatology (Oxford). 54:1369–1379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Delcroix M and Howard L: Pulmonary
arterial hypertension: The burden of disease and impact on quality
of life. Eur Respir Rev. 24:621–629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Almeida C, Almeida I and Vasconcelos C:
Quality of life in systemic sclerosis. Autoimmun Rev. 14:1087–1096.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park EH, Strand V, Oh YJ, Song YW and Lee
EB: Health-related quality of life in systemic sclerosis compared
with other rheumatic diseases: A cross-sectional study. Arthritis
Res Ther. 21:612019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mugii N, Hasegawa M, Matsushita T, Kondo
M, Orito H, Yanaba K, Komura K, Hayakawa I, Hamaguchi Y, Ikuta M,
et al: The efficacy of self-administered stretching for finger
joint motion in Japanese patients with systemic sclerosis. J
Rheumatol. 33:1586–1592. 2006.PubMed/NCBI
|
|
53
|
Volkmann ER and Tashkin DP: Treatment of
Systemic Sclerosis-related Interstitial Lung Disease: A Review of
Existing and Emerging Therapies. Ann Am Thorac Soc. 13:2045–2056.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Young A, Namas R, Dodge C and Khanna D:
Hand impairment in systemic sclerosis: Various manifestations and
currently available treatment. Curr Treatm Opt Rheumatol.
2:252–269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hughes M, Ong VH, Anderson ME, Hall F,
Moinzadeh P, Griffiths B, Baildam E, Denton CP and Herrick AL:
Consensus best practice pathway of the UK Scleroderma Study Group:
Digital vasculopathy in systemic sclerosis. Rheumatology (Oxford).
54:2015–2024. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Alexa ID, Pancu AG, Morosanu AI, Ghiciuc
CM, Lupusoru C, Prada GI and Cepoi V: The impact of self-medication
with NSAIDS/analgesics in a North-Eastern region of Romania.
Farmacia. 62:1164–1170. 2014.
|
|
57
|
Finch MB, Dawson J and Johnston GD: The
peripheral vascular effects of nifedipine in Raynaud's syndrome
associated with scleroderma: A double blind crossover study. Clin
Rheumatol. 5:493–498. 1986.PubMed/NCBI
|
|
58
|
Thompson AE, Shea B, Welch V, Fenlon D and
Pope JE: Calcium-channel blockers for Raynaud's phenomenon in
systemic sclerosis. Arthritis Rheum. 44:1841–1847. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kowal-Bielecka O, Fransen J, Avouac J,
Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M,
Czirjak L, et al EUSTAR Coauthors, : Update of EULAR
recommendations for the treatment of systemic sclerosis. Ann Rheum
Dis. 76:1327–1339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Omair MA, Alahmadi A and Johnson SR:
Safety and effectiveness of mycophenolate in systemic sclerosis. A
systematic review. PLoS One. 10:e01242052015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nihtyanova SI, Brough GM, Black CM and
Denton CP: Mycophenolate mofetil in diffuse cutaneous systemic
sclerosis--a retrospective analysis. Rheumatology (Oxford).
46:442–445. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Stratton RJ, Wilson H and Black CM: Pilot
study of anti-thymocyte globulin plus mycophenolate mofetil in
recent-onset diffuse scleroderma. Rheumatology (Oxford). 40:84–88.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vanthuyne M, Blockmans D, Westhovens R,
Roufosse F, Cogan E, Coche E, Nzeusseu Toukap A, Depresseux G and
Houssiau FA: A pilot study of mycophenolate mofetil combined to
intravenous methylprednisolone pulses and oral low-dose
glucocorticoids in severe early systemic sclerosis. Clin Exp
Rheumatol. 25:287–292. 2007.PubMed/NCBI
|
|
64
|
Takehara K: Treatment of early diffuse
cutaneous systemic sclerosis patients in Japan by low-dose
corticosteroids for skin involvement. Clin Exp Rheumatol. 22 (Suppl
33):S87–S89. 2004.PubMed/NCBI
|
|
65
|
Sharada B, Kumar A, Kakker R, Adya CM,
Pande I, Uppal SS, Pande JN, Sunderam KR and Malaviya AN:
Intravenous dexamethasone pulse therapy in diffuse systemic
sclerosis. A randomized placebo-controlled study. Rheumatol Int.
14:91–94. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Matucci-Cerinic M, Denton CP, Furst DE,
Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ,
Merkel PA, et al: Bosentan treatment of digital ulcers related to
systemic sclerosis: Results from the RAPIDS-2 randomised,
double-blind, placebo-controlled trial. Ann Rheum Dis. 70:32–38.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nguyen VA, Eisendle K, Gruber I, Hugl B,
Reider D and Reider N: Effect of the dual endothelin receptor
antagonist bosentan on Raynaud's phenomenon secondary to systemic
sclerosis: A double-blind prospective, randomized,
placebo-controlled pilot study. Rheumatology (Oxford). 49:583–587.
2010. View Article : Google Scholar : PubMed/NCBI
|
